信达生物-B(01801.HK)续涨11%屡创上市新高 治疗细胞癌新药研究达主要研究终点
信达生物-B(01801.HK)治疗细胞癌新药研究达主要研究终点,该股连续第二天创上市新高,最高见44.7元,现造44元,续涨11%,成交增至524万股,涉资2.22亿元。
信达生物公布,集团与礼来制药共同开发创新PD-1抑制剂达伯舒(信迪利单抗注射液)一项於中国开展II期ORIENT-2研究-达伯舒用於二线治疗晚期或转移性食管鳞状细胞癌患者达到总生存期主要研究终点。详细研究结果将於今年ASCO会议上以壁报讨论形式予以发布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.